Rezolute

09/03/2026

We're excited to share the latest episode of RARECast, featuring an in-depth conversation with Julie Raskin, CEO of Congenital Hyperinsulinism International.

Host Daniel Levine explores the challenges people face living with congenital hyperinsulinism, shining a light on the patient experience and the critical need for advanced care and support solutions.

Tune in to hear how we can better serve this community: https://bit.ly/4zR58M0

08/27/2026

Next week, Congenital Hyperinsulinism International will welcome families, clinicians, researchers, advocates, and partners from around the world to Marseille, France for a three-day Congenital Hyperinsulinism Family Conference.

Rezolute is honored to support and attend this important event, which provides a meaningful opportunity to make connections, learn about the latest in hyperinsulinism care, and show support for an incredible community.

Learn more: https://bit.ly/3SvUfyu

08/24/2026

Some forms of hypoglycemia share a common feature: excessive signaling at the insulin receptor. This is known as hyperinsulinism, or HI for short.

Our investigational therapy, ersodetug*, is designed to act at that receptor which is why it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric and non-bariatric gastrointestinal surgery hypoglycemia (GISH).

Learn more about how ersodetug works: https://bit.ly/4crmghx

*𝘌𝘳𝘴𝘰𝘥𝘦𝘵𝘶𝘨 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘳𝘶𝘨 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘰𝘳 𝘢𝘯𝘺 𝘩𝘦𝘢𝘭𝘵𝘩 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘵𝘺.

08/20/2026

✨ Reminder: Exciting Opportunity! ✨

Rezolute is launching our Tumor Hyperinsulinism Lived Experience Advisory Council, and we're seeking patients, caregivers, and patient advocacy leaders who are affected by or support those living with refractory hypoglycemia related to tumor hyperinsulinism caused by insulin-producing tumors of the pancreas (insulinomas) or other tumors that act similarly.

As lived experience experts and advocacy leaders, your insights will help ensure patient and caregiver perspectives remain at the center of our work, informing initiatives, programs, and community engagement efforts.

📣 Interested in making an impact? Apply today*: https://bit.ly/4z3tdiv

Together, we can drive meaningful progress for the Tumor HI community.

*At this time, eligibility is limited to U.S. based patients, caregivers, and patient advocacy leaders supporting the Tumor HI community. Applications will be reviewed by the Patient Affairs team, and selected applicants will be contacted regarding next steps. Participation is limited, and not all applicants will be selected. Thank you for understanding.

08/18/2026

🎉 New publication in Journal of Clinical Endocrinology and Metabolism (JCEM)!

𝘌𝘳𝘴𝘰𝘥𝘦𝘵𝘶𝘨 𝘧𝘰𝘳 𝘙𝘦𝘧𝘳𝘢𝘤𝘵𝘰𝘳𝘺 𝘏𝘺𝘱𝘰𝘨𝘭𝘺𝘤𝘦𝘮𝘪𝘢 𝘋𝘶𝘦 𝘵𝘰 𝘔𝘢𝘭𝘪𝘨𝘯𝘢𝘯𝘵 𝘐𝘯𝘴𝘶𝘭𝘪𝘯-𝘚𝘦𝘤𝘳𝘦𝘵𝘪𝘯𝘨 𝘛𝘶𝘮𝘰𝘳𝘴 is a retrospective report on outcomes from the compassionate use of our investigational therapy, ersodetug*, in eight individuals with refractory hypoglycemia due to tumor hyperinsulinism (HI).

The administration of ersodetug through our Expanded Access Program (EAP) resulted in reduced hypoglycemia burden for patients, including the ability to discontinue parenteral glucose infusion and allowing discharge from hospital in individuals with severe, refractory tumor HI.

Read the full article: https://bit.ly/4coSGZO

*𝘌𝘳𝘴𝘰𝘥𝘦𝘵𝘶𝘨 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘳𝘶𝘨 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘣𝘦𝘦𝘯 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘰𝘳 𝘢𝘯𝘺 𝘩𝘦𝘢𝘭𝘵𝘩 𝘢𝘶𝘵𝘩𝘰𝘳𝘪𝘵𝘺.

AbstractBackground. Refractory hypoglycemia is common in malignant insulin-secreting tumors and is associated with substantial morbidity. Ersodetug is a fu

08/14/2026

We’ll be at the Midwest Endocrinology Society Annual Meeting in Bloomington, MN for the next few days, connecting with leaders across the endocrinology community.

We are looking forward to engaging in discussions about advancing hyperinsulinism care and raising awareness of this life-threatening rare disease. Please stop by to say hello to our team!

Event details: https://bit.ly/45u0tSf

08/13/2026

Congenital hyperinsulinism (HI) is a life-threatening rare disease most commonly diagnosed in the first year of life, with the potential for serious, lasting neurologic consequences. Unfortunately, today's treatment options often have suboptimal efficacy, are poorly tolerated, and come with serious safety concerns.

We're working to change that. Learn how we're developing a novel therapy designed to treat all forms of HI: https://bit.ly/4fUkXsi

08/11/2026

At the Cook Children's Health Care System’s Hyperinsulinism Center in Fort Worth, Texas, Medical Director Paul Thornton and his team are committed to helping children living with through multidisciplinary treatment and research. For 15 years, they have pioneered innovative treatments and practices, earning recognition as a Congenital Hyperinsulinism International Center of Excellence.

Thank you to this team and to all hyperinsulinism specialists around the world who bring their critical expertise to patients and caregivers.

Learn more about the Cook Children’s Hyperinsulinism Center and their important work here: https://bit.ly/4i0bmmb

08/05/2026

Over the weekend, we attended the Texas Endocrinology Association’s 2026 Annual Meeting in Dallas. We were grateful to connect with endocrinologists and other healthcare professionals to discuss opportunities to increase awareness of rare endocrine diseases associated with hyperinsulinism and help improve patient care.

We're proud that UT MD Anderson is a participating site in the upLIFT clinical trial and is actively enrolling eligible patients with tumor-induced refractory hypoglycemia.

Learn more about upLIFT: https://bit.ly/4wbVrEX

07/29/2026

✨ Exciting Opportunity! ✨

Rezolute is launching our Tumor Hyperinsulinism Lived Experience Advisory Council, and we're seeking patients, caregivers, and patient advocacy leaders who are affected by or support those living with refractory hypoglycemia related to tumor hyperinsulinism caused by insulin-producing tumors of the pancreas (insulinomas) or other tumors that act similarly.

As lived experience experts and advocacy leaders, your insights will help ensure patient and caregiver perspectives remain at the center of our work, informing initiatives, programs, and community engagement efforts.

📣 Interested in making an impact? Apply today*: https://bit.ly/4z3tdiv

Together, we can drive meaningful progress for the Tumor HI community.

*At this time, eligibility is limited to U.S. based patients, caregivers, and patient advocacy leaders supporting the Tumor HI community. Applications will be reviewed by the Patient Affairs team, and selected applicants will be contacted regarding next steps. Participation is limited, and not all applicants will be selected. Thank you for understanding.